Clinical Trial
doi: 10.1016/j.jaci.2020.02.002.
Epub 2020 Feb 19.
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy
Affiliations
- PMID: 32084443
- DOI: 10.1016/j.jaci.2020.02.002
Item in Clipboard
Clinical Trial
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy
J Allergy Clin Immunol.
2020 Jun.
No abstract available
Comment in
-
Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis.J Allergy Clin Immunol. 2020 Sep;146(3):683. doi: 10.1016/j.jaci.2020.05.054. Epub 2020 Jul 24. J Allergy Clin Immunol. 2020. PMID: 32713686 No abstract available.
-
Reply.J Allergy Clin Immunol. 2020 Sep;146(3):683-684. doi: 10.1016/j.jaci.2020.05.053. Epub 2020 Jul 24. J Allergy Clin Immunol. 2020. PMID: 32713687 No abstract available.
Similar articles
-
Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053. Epub 2019 Jun 13. J Allergy Clin Immunol Pract. 2019. PMID: 31201938
-
Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.J Allergy Clin Immunol. 2017 Nov;140(5):1464-1466.e4. doi: 10.1016/j.jaci.2017.06.010. Epub 2017 Jul 4. J Allergy Clin Immunol. 2017. PMID: 28687231 Clinical Trial. No abstract available.
-
Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.Int Arch Allergy Immunol. 2024;185(3):253-259. doi: 10.1159/000534902. Epub 2023 Nov 30. Int Arch Allergy Immunol. 2024. PMID: 38035559
-
Biologics for oral corticosteroid-dependent asthma.Allergy Asthma Proc. 2020 May 1;41(3):151-157. doi: 10.2500/aap.2020.41.200015. Allergy Asthma Proc. 2020. PMID: 32375958 Review.
-
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29133975 Free PMC article. Review.
Cited by
-
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.J Asthma Allergy. 2023 Sep 4;16:915-932. doi: 10.2147/JAA.S413064. eCollection 2023. J Asthma Allergy. 2023. PMID: 37692126 Free PMC article.
-
Positionspapier: Empfehlungen zur Behandlung der chronischen Rhinosinusitis während der COVID-19-Pandemie im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC) – Diese Empfehlungen basieren auf dem EAACI Positionspapier „Treatment of chronic RhinoSinusitis with nasal polyps (CRSwNP) in the COVID-19 pandemics – An EAACI Position Paper”, Allergy, 2020 und wurden auf die Situation im deutschen Gesundheitswesen angepasst.Laryngorhinootologie. 2020 Jun;99(6):356-364. doi: 10.1055/a-1164-9696. Epub 2020 May 8. Laryngorhinootologie. 2020. PMID: 32384572 Free PMC article. German.
-
Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma.Front Med (Lausanne). 2023 Mar 22;10:1129300. doi: 10.3389/fmed.2023.1129300. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37035303 Free PMC article. Review.
-
Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.Lung India. 2025 May 1;42(3):231-244. doi: 10.4103/lungindia.lungindia_442_24. Epub 2025 Apr 29. Lung India. 2025. PMID: 40296395 Free PMC article.
-
Eosinophils and eosinophilic immune dysfunction in health and disease.Eur Respir Rev. 2022 Jan 25;31(163):210150. doi: 10.1183/16000617.0150-2021. Print 2022 Mar 31. Eur Respir Rev. 2022. PMID: 35082127 Free PMC article. Review.
